Intelligent automation in pharma has been over-promised and under-delivered for a decade. Most automation budgets have gone to clinical trial operations, regulatory submissions, and pharmacovigilance, with mixed results. The question is not whether IA belongs in pharma; it is which parts of the pipeline it actually accelerates.
Where IA lands well
Three areas where the operating model is well-suited to agentic AI: regulatory document drafting, pharmacovigilance case processing, and clinical operations data flow. All three are document-heavy, rules-driven, and audit-grade in their output requirements. The AI Factory's quality gate model maps cleanly onto regulatory expectations.
Where IA struggles
Drug discovery itself is harder. Not because AI cannot contribute, but because the scientific judgement layer is denser. The right answer there is augmentation, not autonomy. Agentic AI as a co-pilot for medicinal chemists and translational scientists, not as a replacement for the scientific decision.
"Pharma's structural strength is the rigour of its operating processes. IA inside that rigour accelerates; IA that bypasses it fails."
The change that matters
The single highest-leverage change is to treat IA as an operating-model question rather than a technology question. Regulatory affairs teams need to own the agent. Pharmacovigilance teams need to own the agent. The agent is part of the team, not a tool the team uses.
The takeaway. Intelligent automation in pharma will land where the operating model is rebuilt around it, and stall where it is not. The 70%+ AI project failure rate quoted across industry research applies to pharma too; the AI Factory operating model is built to break that pattern.